Corporate News Report
On Saturday, 24 November 2026, Illumina Inc. (NASDAQ: ILMN) experienced a decline of 4.76 % in its share price during the 24‑hour trading period that closed at 02:41 AM Central Europe. At the time of writing, the stock trades at approximately USD 269.42 on major exchanges. The company’s current share supply is 151 million, giving it a market capitalisation of roughly USD 42.7 billion. In the previous 24 hours, investors exchanged about USD 599.1 million worth of Illumina shares.
Since the end of last month, Illumina’s shares have risen 5.49 %. Its 200‑day simple moving average sits at USD 172.30. The all‑time high for the stock over the past 52 weeks reached USD 309.35 on 10 June 2026, while the 52‑week low fell to USD 94.00 on 30 October 2025.
Comparative Performance of Peer Companies
The performance of several comparable stocks in the last 24 hours provides context for Illumina’s recent decline:
| Company | Ticker | 24‑hour change | Current price | Market Capitalisation | P/E Ratio |
|---|---|---|---|---|---|
| Comfort USA | FIX | -8.7 % | USD 1 160.86 | USD 49.3 billion | 34.48 |
| Agilent | A | -2.17 % | USD 173.07 | USD 50.1 billion | 35.03 |
| Ciena | CIEN | -10.71 % | USD 320.26 | USD 51.2 billion | 80.63 |
| Humana | HUM | -1.05 % | USD 422.42 | USD 51.1 billion | 40.29 |
| Edwards Lifesciences | EW | +1.91 % | USD 89.07 | USD 51.0 billion | 52.45 |
Illumina’s performance contrasts with the mixed outcomes of its peers, some of which have seen sharp declines, while Edwards Lifesciences has posted a modest gain.
Company Overview
Illumina Inc. operates in the health‑care and life‑sciences sector, focusing on the development, manufacturing, and marketing of integrated systems for large‑scale genetic variation and biological function analysis. The company’s product suite serves sequencing, genotyping, and gene‑expression markets, catering to genomic research centres, pharmaceutical firms, academic institutions, and biotechnology companies. Illumina’s services are designed to accelerate scientific discovery and drug development through high‑throughput genomic technologies.
Illumina’s initial public offering occurred on 28 July 2000, and the company is listed on the Nasdaq stock exchange. For further details, interested parties may visit the firm’s website at www.illumina.com .
